accurate quantification of the expression of 6 VEGF variants, can be a promising tool for the elucidation of their role in promoting physiologic and pathologic angiogenesis. Our method can be applied to various samples for the separate quantification of a single VEGF splice variant of interest or of all 6 variants together and could serve as a model for the development of real-time RT-PCR assays for the quantification of other alternatively spliced genes.
14. Ovstebo R, Haug K〉, Lande K, Kierulf P. (6, 8 ) , whereas OmniPlex uses in vitro libraries with fragmented DNA (ϳ1.5 kb) to amplify the entire genome by PCR (9 ) .
To apply WGA technology to BeadArray TM genotyping (Illumina), the utility of MDA and/or OmniPlex on DNA samples derived from lymphoblast cells has been evaluated (9, 10 ) . In this study, we determined the genotyping success rate and reliability of 2 MDA variants (8, 11 ) and OmniPlex with and without 7-deaza-dGTP, using buccal swabs, whole blood, dried blood spots, and sheared genomic DNA on 1260-and 1228-SNP BeadArray panels. The 7-deaza-dGTP nucleotide analog was included in an attempt to ensure amplification of GC-rich DNA.
After Institutional Review Board approval and informed consent were obtained, DNA samples were collected from participants in a study of oral clefts (12 ) . Genomic DNA samples were prepared from peripheral blood by protein precipitation (13 ) . Buccal cells were obtained by rubbing the inside of cheeks with a brush (Medical Packaging), and DNA was extracted with 600 L of 50 mmol/L NaOH (2 ). For blood spot samples dried on Guthrie cards, two to three 2-mm circles punched from the blood spots with a micro-punch (Fitzco) were placed in 5 g/100 mL Chelex ® 100 chelating resin (Bio-Rad Laboratories) (14 ) and treated as described (blood spot A) (15 ) or stored at Ϫ20°C for ϳ3 years (blood spot C). As an alternative method, 2 to 3 circles punched from the blood spots were placed in a cell lysis solution (10 L of 0.2 mol/L KOH at 65°C for 10 min), neutralized with 10 L of 0.2 mol/L tricine, and diluted with 80 L of sterile H 2 O (blood spot O). The paper punch was cleaned with compressed air to avoid cross-contamination. To evaluate the effect of the molecular weight of the template DNA, genomic DNA was randomly sheared with DNase I into fragments of ϳ20, 5, and 2 kb (16 ). The concentrations of DNA samples were determined by PicoGreen ® dsDNA Quantitation (Molecular Probes).
The minimum amount of template DNA for MDA was assessed over a 10 5 range of genomic DNA (3 pg to 300 ng). Whether MDA products were human DNA or artifacts of WGA was determined by PCR with primers specific to a human DNA sequence (LMX1B exon 3) (17 ) and a short tandem repeat marker (AFM143ϫd12) and separation by 2% agarose gel electrophoresis. DNA samples (ϳ1 ng) and both positive and negative controls were amplified by use of a GenomiPhi TM or TempliPhi TM Kit according to the manufacturer's instructions (Amersham Biosciences). A 50-ng aliquot of DNA at 1-2 ng/L for each sample, identical to that used for MDA, was sent to Rubicon Genomics for amplification with and without 7-deaza-dGTP.
A panel of 1260 SNP markers for testing WGA methods (plate 1) was selected from a subset (GS0005002-OPA) of the Linkage III SNP panel generated by Illumina, and a more reliable 1228-SNP panel was selected for testing sources of DNA and sheared DNA (plate 2 The success rate was computed as (1 Ϫ proportion of missing genotypes) ϫ100 (%), where the proportion of missing genotypes was calculated as the number of genotypes with a Gene Call score Ͻ0.25 over the total number of genotypes. After SNPs with a Gene Call score Ͻ0.25 were dropped, reliability was estimated with the proportion of mismatches in genotypes between unamplified and amplified genomic DNA, with and without consideration of allele loss. The distributions of SNP genotypes were analyzed by different data quality thresholds: those containing all data, a moderately conservative group (median Gene Call score Ͼ0.4), and a very conservative group (Ͼ0.5). The significance of differences between the 2 compared groups was tested by a paired t-test or 2-sided t-test (18 ) . Statistical analyses were performed by Intercooled STATA 7.0 (STATA Co.).
Input of genomic DNA Ͼ0.03 ng yielded sufficient and reliable amplified product for a run of BeadArray genotyping requiring 3 g by either MDA method. Mean (SE) yields were 377 (11), 217 (10), 175 (17) , and 125 (12) ng/L from each method for GenomiPhi, TempliPhi, OmniPlex without 7-deaza-dGTP, and OmniPlex with 7-deazadGTP, respectively. With DNA template from sources other than whole blood, however, more input DNA (Ͼ0.5 ng) was required.
As shown in (Fig. 1) . Regarding sources of DNA, the success rate of genotyping was 99.98% for unamplified genomic DNA, and the rates decreased with amplified DNA, particularly in DNA amplified from blood spots (99.5%-31.2%; Table 1 ). DNA amplified from buccal swabs (0.35% without 2 outliers) gave low reliability similar to DNA amplified from whole blood (0.07%). DNA amplified from blood spots, however, gave less reliability (14.5%-44.9%), more allele loss (11.8%-41.3%), and more variability across individuals, for all extraction methods ( Table 1) .
The size of DNA fragments was Ͼ23 kb in most genomic DNA samples, but it was ϳ20 kb in buccal swabs and ranged from 2 to 10 kb in blood-spot samples. Two buccal swab samples yielding low reliability contained predominantly low-molecular-weight DNA (2-20 kb). Both success rates and reliability of unamplified DNA (99.98% success rate) and unfragmented DNA amplified from whole blood (99.3% success rate and 0% mismatches) were high among 1228 SNPs. These rates decreased, however, for sheared DNA samples (98.5%, 94.4%, and 76.4% success rate; 2.4%, 8.2%, and 28.9% mismatches for 20, 5, and 2 kb, respectively). Increasing the threshold of data quality (median Gene Call score Ͼ0.5) had a minimal effect on the success rate of genotyping, but it reduced the number of genotypes obtained from blood spots (see Table 1 in the Data Supplement that accompanies the online version of this Technical Brief at http://www.clinchem.org/content/vol51/issue8/) and sheared DNA samples without any increase in reliability (data not shown).
Previous studies have reported high genotype concordance rates (Ͼ99.8%) with the use of MDA or OmniPlex with genomic DNA (9, 10, 19 -21 ) and have suggested that MDA carried out directly from crude biological samples can be used immediately for subsequent assays with no need to measure DNA concentration or purification (6, 22 ) . In our study, however, both success rate and reliability were highest for DNA amplified by GenomiPhi and lowest for DNA amplified by OmniPlex with 7-deaza-dGTP. Amplification of DNA from buccal swabs was less successful and less reliable than DNA from whole blood but superior to DNA from dried blood spots, despite the use of 3 independent extraction methods. The reduced success rate and reliability may result from its low molecular weight because sheared genomic DNA (Ͻ20 kb) also gave a low success rate and reliability.
The successful amplification of human DNA requires a small amount of genomic template of appropriate quality of input DNA (e.g., 0.5 ng of unfragmented DNA). Template DNA for MDA, therefore, should be shown to be Ͼ20 kb by visualization of DNA on an agarose gel, and whether DNA amplified by MDA is human or bacterial DNA must be determined by amplification of human DNA sequences by PCR before subsequent analyses, particularly when there is very little DNA. In most cases, DNA from other sources is not as good a template for WGA as whole blood and also cannot be used without amplification for BeadArray assay. In future experiments, we will consider the cut point of 0.25 for Gene Call scores adequate for BeadArray genotyping.
In conclusion, our study suggests that MDA represents an efficient and reliable method to maximize DNA resources from whole blood and buccal swabs for BeadArray SNP genotyping. DNA samples that are isolated from dried blood spots or are degraded and fragmented, however, are inappropriate for MDA. The toll-like receptor-4 (TLR4; OMIM*603030), a member of a large family of transmembrane proteins, is predominantly expressed on monocytes and macrophages (1 ). TLR4 is involved in various diseases and in innate and adaptive immunity (2 ) , and it is thought to be crucial in mediating lipopolysaccharide effects (3 ). The common co-segregating variants, Asp299Gly and Thr399Ile, affect the extracellular domain of the TLR4 receptor. These variants are associated in humans with a blunted response to inhaled lipopolysaccharide in humans and lead to an altered host immune response to pathogens (4 ) .
The corresponding TLR4 genetic variations A896G (D299G; OMIM*603030.001) and C1196T (T399I, OMIM*603030.002) have been analyzed by use of DNA sequencing (4 ), restriction fragment length polymorphism analysis (5 ), MGB-TaqMan probes, matrix-assisted laser desorption/ionization analysis (6 ), and LightCycler hybridization probes (7 ). We developed a new homogeneous assay for genotyping of A896G and C1196T by use of locked-nucleic-acid (LNA)-modified SimpleProbe oligomers (8 ) on the LightTyper instrument (Roche). This assay provides a specific and sensitive method for highthroughput genotyping of these TLR4 mutations and may be useful for evaluating the presence of TLR4 polymorphisms in patients and to predict susceptibility to bacterial infection. Genotyping of 96 samples in a short time period using DNA from various sources is possible with this method. Furthermore, it has a wide dynamic range and therefore is applicable for DNA sets with varying DNA yields and quality.
DNA was extracted from whole blood (n ϭ 120) by use of the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer's guidelines. DNA from serum (n ϭ 377) was extracted by use of the Magna Pure LC DNA Isolation Kit I (Roche).
Mutation detection for the LightTyper was based on a reported protocol (7 ), but we used SimpleProbe oligomers (Table 1) instead of pairs of hybridization probes. These singular probes use a terminal self-quenching fluorophore. The quenching moiety changes its properties when stacked with the neighboring base during binding, lowering quenching and increasing the fluorescence signal (515 nm). Clinical Chemistry 51, No. 8, 2005 
